Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates

2006/12/30 by Susan E. Sloan, Susan Sloan, Cathleen A. Hanlon +13 · 26 citations
Immunology and Microbiology · Medicine · #Rabies epidemiology and control #Viral Infections and Outbreaks Research #Virology and Viral Diseases

paper · doi:10.1016/j.vaccine.2006.12.031

Cited by

• Structure of trimeric pre-fusion rabies virus glycoprotein in complex with two protective antibodies
• The growth and potential of human antiviral monoclonal antibody therapeutics. [europepmc]
• Lyssaviruses: current trends. [europepmc]
• Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus. [europepmc]
• Characterization of a human antibody fragment Fab and its calcium phosphate nanoparticles that inhibit rabies virus infection with vaccine. [europepmc]
• Immunity to fish rhabdoviruses. [europepmc]
• Monoclonal antibodies for prophylactic and therapeutic use against viral infections. [europepmc]
• A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life. [europepmc]
• Development of broad-spectrum human monoclonal antibodies for rabies post-exposure prophylaxis. [europepmc]
• Development and characterization of novel chimeric monoclonal antibodies for broad spectrum neutralization of rabies virus. [europepmc]
• SYN023, a novel humanized monoclonal antibody cocktail, for post-exposure prophylaxis of rabies. [europepmc]
• Antibody therapies for the prevention and treatment of viral infections. [europepmc]
• In Vivo Efficacy of a Cocktail of Human Monoclonal Antibodies (CL184) Against Diverse North American Bat Rabies Virus Variants. [europepmc]
• Establishment of a Chinese street rabies virus library and its application for detecting neutralizing activity. [europepmc]
• A novel ELISA for quantification of glycoprotein in human rabies vaccines using a clinically proven virus neutralizing human monoclonal antibody. [europepmc]
• In Vivo Efficacy of SYN023, an Anti-Rabies Monoclonal Antibody Cocktail, in Post-Exposure Prophylaxis Animal Models. [europepmc]
• Recent advances in therapeutic applications of neutralizing antibodies for virus infections: an overview. [europepmc]
• Advances in the progress of monoclonal antibodies for rabies. [europepmc]
• A cocktail of human monoclonal antibodies broadly neutralizes North American rabies virus variants as a promising candidate for rabies post-exposure prophylaxis. [europepmc]
• Unmodified rabies mRNA vaccine elicits high cross-neutralizing antibody titers and diverse B cell memory responses. [europepmc]
• Antiviral mechanisms of two broad-spectrum monoclonal antibodies for rabies prophylaxis and therapy. [europepmc]
• Fc-FcγR interactions during infections: From neutralizing antibodies to antibody-dependent enhancement. [europepmc]
• Deep mutational scanning of rabies glycoprotein defines mutational constraint and antibody-escape mutations. [europepmc]
• Research trends in anti-rabies virus monoclonal antibody: A bibliometric analysis. [europepmc]
• Rabies glycoprotein engineering for improved stability and expression. [europepmc]
• A SynB1-conjugated antibody cocktail crosses the blood-brain barrier to produce a therapeutic effect on rabies. [europepmc]